Etrasimod - Arena Pharmaceuticals

Drug Profile

Etrasimod - Arena Pharmaceuticals

Alternative Names: APD 334

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arena Pharmaceuticals
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma; Ulcerative colitis

Most Recent Events

  • 10 Nov 2017 Arena Pharmaceuticals completes enrolment in its phase II trial for Ulcerative colitis in Australia, Belgium, Bulgaria, the Czech Republic, France, Germany, Hungary, Israel, Latvia, Lithuania, New Zealand, Poland, Spain, Ukraine, United Kindgom, USA and Canada (NCT02447302)
  • 07 Nov 2017 Phase-II clinical trials in Primary biliary cirrhosis (In adults, In the elderly) in USA (PO) (NCT03155932)
  • 22 Aug 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top